ScreenPoint Medical expands in Spain with SACYL - EUSOBI 2025

Nijmegen, The Netherlands and Castilla y León, Spain September 24, 2025 – Today, ScreenPoint Medical announces its partnership with Sacyl, the healthcare services system of the Castilla y León region in Spain. ScreenPoint’s partnership with Sacyl will bring Transpara Breast AI to around 15-17 breast cancer screening centers across the region. The most clinically validated AI for breast cancer detection on the market, Transpara Breast AI provides radiologists with a 'second pair' of eyes to help detect cancers earlier and reduce breast screening workload.

Operating across a large section of Central Spain, the Ministry of Health of the Regional Government of Castile and León offers free mammography screening to all women between the ages of 45 and 74 living in the region. Through this partnership, Sacyl seeks to improve outcomes for the women it serves by leveraging AI that is proven to increase cancer detection while helping radiologists review mammograms more efficiently: in first of its kind MASAI randomized controlled trial from Sweden, Transpara improved cancer detection by 29% while reducing workload by 44%.

After extensive vendor comparison, Sacyl selected ScreenPoint Medical as its AI vendor of choice due to its proven track record as well as the breadth of clinical evidence supporting its solutions. Transpara Detection has been used and proven in other regions across Spain, including the Córdoba Breast Cancer Screening Program (CBCSP), SESCAM in Castilla-La Mancha, and SERGAS in Galicia. Results from Córdoba published in 2023 highlight an increase in the breast cancer detection rate in a real-world screening scenario involving over 10,000 women. Transpara also increased the positive predictive value of recalled women across both 2D and 3D imaging modalities, helping the program address cancer early and effectively.

Sacyl will implement the Transpara Detection algorithm, designed to spot cancers that might otherwise be missed, the Transpara Density algorithm, which assesses breast density for each woman, and Transpara Temporal Comparison, which tracks mammographic changes to better understand changes in breast cancer risk over time.

“Spain has been at the vanguard of adoption in Breast AI,” said Pieter Kroese, CEO at ScreenPoint Medical. “We hope to build on Sacyl’s screening successes to help serve the women of Castilla y León, an impact that extends to women, families, and communities across the region and across the country.”